KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Esperion Therapeutics (ESPR) EPS (Weighted Average and Diluted) (2018 - 2025)

Esperion Therapeutics (ESPR) has disclosed EPS (Weighted Average and Diluted) for 8 consecutive years, with $0.32 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, EPS (Weighted Average and Diluted) rose 328.57% year-over-year to $0.32, compared with a TTM value of -$0.11 through Dec 2025, up 60.71%, and an annual FY2025 reading of -$0.11, up 60.71% over the prior year.
  • EPS (Weighted Average and Diluted) was $0.32 for Q4 2025 at Esperion Therapeutics, up from -$0.16 in the prior quarter.
  • Across five years, EPS (Weighted Average and Diluted) topped out at $0.34 in Q1 2024 and bottomed at -$3.5 in Q1 2021.
  • Average EPS (Weighted Average and Diluted) over 5 years is -$0.76, with a median of -$0.48 recorded in 2023.
  • Peak annual rise in EPS (Weighted Average and Diluted) hit 328.57% in 2025, while the deepest fall reached 161.76% in 2025.
  • Year by year, EPS (Weighted Average and Diluted) stood at -$1.53 in 2021, then skyrocketed by 51.63% to -$0.74 in 2022, then soared by 32.43% to -$0.5 in 2023, then surged by 72.0% to -$0.14 in 2024, then soared by 328.57% to $0.32 in 2025.
  • Business Quant data shows EPS (Weighted Average and Diluted) for ESPR at $0.32 in Q4 2025, -$0.16 in Q3 2025, and -$0.06 in Q2 2025.